<DOC>
	<DOCNO>NCT00674635</DOCNO>
	<brief_summary>This randomize , double-blinded , placebo-controlled adaptive , dose find study investigate safety , tolerability , PK , PD efficacy single repeat intravenous infusion GSK315243A patient active rheumatoid arthritis . The study divide 2 part : Part A adaptive , dose find phase provide safety , tolerability , PK PD single intravenous infusion . Part B repeat dose phase provide safety , tolerability , PK , PD efficacy follow repeat intravenous infusion select dose level .</brief_summary>
	<brief_title>Phase II Study Evaluating Safety Efficacy GSK315234A Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Males females 18 75 year age , inclusive . All subject must use acceptable contraception ( define study restriction section ) ensure pregnancy occur course study least 12 week dose male 32 week dose female ( see Section 7.1 contraception detail ) . Body mass index within range 18.5 35 kg/m2 inclusive , addition weight range 55 95kg . The subject must capable give informed consent comply study requirement timetable . The subject must diagnosis RA accord revised 1987 criterion American College Rheumatology ( ACR ) ( see Appendix 2 ) . The subject must DAS28 disease activity score great 4.2 screen predose . The subject must CRP serum level &gt; /0.5mg/dl ESR level 28mm/hour screen predose The subject NOT receive biological therapy past , include biologicals treatment rheumatoid arthritis The subject must liver function test include alanine transaminase ( ALT ) aspartate transaminase ( AST ) within 1.5 time upper limit normal ( ULN ) alkaline phosphatase ( ALP ) within 3 time ULN screening . The patient must also total bilirubin within ULN screen . The subject must receive least 3 month methotrexate must stable dose methotrexate ( 25 mg/week ) least 8 week prior screen willing remain dose throughout study . If sulfasalazine take addition methotrexate , subject must stable dose least 4 week prior screen willing remain dose throughout study . If hydroxychloroquine chloroquine take addition methotrexate , subject must stable dose least 3 month prior screen willing remain dose throughout study . Those subject oral antirheumatic therapy , may include Non Steroidal Anti Inflammatory Drugs ( NSAIDs ) , COX2 inhibitor , oral glucocorticoid e.g . prednisolone ( £10mg/day ) must stable dose regimen least 4 week prior screen willing remain regime throughout study . Subjects receive intramuscular glucocorticoid e.g methylprednisolone ( £120 mg/month ) must stable dose regimen least 3 month prior screen willing remain regimen throughout study . The subject must stable dose folate supplement ( 5 mg/week ) least 4 week prior Any clinically relevant abnormality identify screen medical assessment , laboratory examination ( e.g . haematology parameter outside normal limit ) , ECG ( 12 Lead Holter ) . The subject positive Hepatitis B surface antigen Hepatitis C antibody result screening . The subject history elevate liver function test one occasion ( ALT , AST ALP &gt; 3 x Upper Limit Normal ( ULN ) ; total bilirubin &gt; 1.5 x ULN ) past 6 month . Previous exposure past infection cause Mycobacterium tuberculosis The subject acute infection . The subject history repeat , chronic opportunistic infection , opinion investigator and/or GSK medical monitor , place subject unacceptable risk participant trial . The subject history malignancy , except surgically cure basal cell carcinoma female cure cervical carcinoma ( &gt; 2 yrs prior ) . The subject history human immunodeficiency virus ( HIV ) immunodeficiency disease . The subject whose calculated creatinine clearance le 50ml/min The subject significant cardiac , pulmonary , metabolic , renal , hepatic gastrointestinal condition , opinion investigator and/or GSK medical monitor , place subject unacceptable risk participant trial . The subject take cyclosporine , leflonomide , cyclophosphamide azathioprine within 1 month screening . Subjects take cyclosporine , leflonomide , cyclophosphamide azathioprine past must recover drug related adverse event . The subject take gold salt dpenicillamine within 1 month prior screen . Subjects take gold salt dpenicillamine past must recover drug relate adverse event . The subject receive intraarticular glucocorticoid within 1 month screening . Recent history bleeding disorder , anaemia , peptic ulcer disease , haematemesis gastrointestinal bleeding Subjects history haematological disease acquire platelet disorder , include druginduced thrombocytopaenia , acute idiopathic thrombocytopaenia von Willebrand 's disease . Subjects know risk intracranial haemorrhage include Central Nervous System ( CNS ) surgery within last 12 month , arterial vascular malformation , aneurysm , significant close head trauma within 6 month incident investigator and/or medical monitor considers relevant . The subject Hb &lt; 10 g/deciliter ( dL ) platelet count &lt; 150 x 109/Liter ( L ) Donation blood excess 500 ml within 56 day period prior dose An unwillingness male subject abstain sexual intercourse pregnant lactating woman ; unwillingness male subject use condom spermicide addition female partner use another form contraception interuterine device ( IUD ) , diaphragm spermicide , oral contraceptive , injectable progesterone , subdermal implant levonorgestrel tubal ligation woman could become pregnant least 12 week dose An unwillingness female subject child bear potential use adequate contraception , define study restriction section . If necessary , woman nonchild bear potential ( i.e . postmenopausal surgically sterile e.g . tubal ligation hysterectomy bilateral oophorectomy ) confirm . Postmenopausal status confirm serum follicle stimulate hormone ( FSH ) oestradiol concentration screen . Surgical sterility define female document hysterectomy , tubal ligation bilateral oophorectomy . The subject history use drug abuse within 12 month prior screen . History regular alcohol consumption exceed average weekly intake great 21 unit average daily intake great 3 unit ( male ) average weekly intake great 14 unit average daily intake great 2 unit ( female ) . Subjects regularly consume 12 unit alcohol 24h period also exclude . 1 unit equivalent halfpint ( 220ml ) beer/lager 1 ( 25ml ) measure spirit 1 glass ( 125ml ) wine . Positive pregnancy test lactate screening . Participation trial investigational drug within 3 month 5 halflives ( whichever longer )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>adaptive study ,</keyword>
	<keyword>DAS28 ,</keyword>
	<keyword>monoclonal antibody</keyword>
	<keyword>GSK315234A ;</keyword>
	<keyword>rheumatoid arthritis ,</keyword>
</DOC>